Sanofi boosts its immunology pipeline

Sanofi announced two major developments in its specialty portfolio: FDA accelerated status for venglustat in a rare neurological indication, and, more importantly, approval in Japan for Dupixent in bullous pemphigoid, a first targeted therapy in this market. These updates improve visibility on the group’s innovative treatments and confirm the strategic value of Dupixent, already a key growth driver. The stock-market impact is broadly positive, as the announcements strengthen commercial prospects and enhance confidence in Sanofi’s pipeline. However, the upside could be partially offset by competition and by the fact that some regulatory milestones do not translate immediately into meaningful sales.